公司根据上述决议进行了现金管理。部分产品现已到期赎回。现就具体情 况公告如下： 一、现金管理产品到期赎回情况 1 证券代码：300765 证券简称：新诺威 公告编号：2024-101 石药创新制药股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2024 年 3 月 13 日召开第 六届董事会第十三次会议、第六届监事会第十次会议，于 2024 年 4 月 9 日召开 2023 年年度股东大会，会议审议并通过了《关于使用部分闲置募集资金及自有 资金进行现金管理的议案》。在不影响募集资金投资项目建设和公司正常经营的 情况下，公司及子公司使用不超过人民币 5.00 亿元（含本数）额度的闲置募集资 金及不超过人民币 5.00 亿元（含本数）的自有资金进行现金管理，投资安全性 高、流动性好的保本型产品（包括结构性存款、大额存单等），使用期限自股东 大会审议通过之日起 12 个月内有效。在上述额度及决议有效期内，业务可循环 滚动开展。具体内容详见巨潮资讯网（http ...

证券代码：300765 证券简称：新诺威 公告编号：2024-100 石药创新制药股份有限公司 2024 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过的决议的情形。 一、会议的召开和出席情况 1. 股东大会的届次：2024 年第三次临时股东大会。 2. 会议召集人：公司董事会。 3. 会议主持人：公司董事长姚兵。 4. 会议召开的日期、时间： （1）现场会议召开时间：2024 年 10 月 31 日（星期四）下午 14:30 开始。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2024 年 10 月 31 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交 易所互联网投票系统投票的具体时间为：2024 年 10 月 31 日 9:15-15:00。 5. 现场会议召开地点：河北省石家庄市高新区中山东路 896 号公司会议室。 6. 出席会议的股东人数： 通过现场和网 ...

北京市君泽君律师事务所 关于石药创新制药股份有限公司 发行股份及支付现金购买资产并募集配套资金暨关联交易 之 相关内幕信息知情人买卖股票自查报告的 专项核查意见 北京市东城区金宝街 89 号金宝大厦 11 层 邮编：100005 11F, Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing 100005, P.R.C. 电话（Tel）： （86-10） 6652 3388 传真（Fax）：（86-10）6652 3399 网址（Website）： www.junzejun.com 电子信箱（E-mail）：jzj@junzejun.com 北京市君泽君律师事务所 关于石药创新制药股份有限公司 发行股份及支付现金购买资产并募集配套资金暨关联交易之 相关内幕信息知情人买卖股票自查报告的 专项核查意见 君泽君[2024]证券字 2024-007-2-1 号 致：石药创新制药股份有限公司 北京市君泽君律师事务所（以下简称"本所"）接受石药创新制药股份有限 公司（以下简称"上市公司"或"公司"）的委托，担任其发行股份及支付现金购买 资产并募集配套资金暨 ...

证券代码：300765 证券简称：新诺威 公告编号：2024-099 石药创新制药股份有限公司 关于本次交易相关内幕知情人买卖股票情况的 自查报告的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"石药创新"、"公司"或"上市公司"） 拟以发行股份及支付现金方式购买石药集团维生药业（石家庄）有限公司（以下 简称"维生药业"）、石药（上海）有限公司、石药集团恩必普药业有限公司（以 下简称"恩必普药业"）合计持有的石药集团百克（山东）生物制药股份有限公司 100%股权，并募集配套资金（以下简称"本次交易"）。 根据《上市公司重大资产重组管理办法》《公开发行证券的公司信息披露内 容与格式准则第 26 号——上市公司重大资产重组》《深圳证券交易所上市公司 自律监管指引第 8 号——重大资产重组》等文件的规定，公司对本次交易相关内 幕信息知情人买卖股票的情况进行了自查，本次自查的相关情况如下： 一、本次交易的内幕信息知情人自查期间 本次交易的内幕信息知情人的自查期间为：上市公司本次交易股票停牌日 （2024 年 1 月 11 日） ...

国投证券股份有限公司、中信证券股份有限公司 关于石药创新制药股份有限公司本次交易 相关内幕知情人买卖股票情况的自查报告的核查意见 石药创新制药股份有限公司（以下简称"石药创新"、"公司"或"上市公司"） 拟以发行股份及支付现金方式购买石药集团维生药业（石家庄）有限公司、石药 （上海）有限公司、石药集团恩必普药业有限公司（以下简称"恩必普药业"）合 计持有的石药集团百克（山东）生物制药股份有限公司（以下简称"标的公司"） 100%股权，并募集配套资金（以下简称"本次交易"）。 国投证券股份有限公司、中信证券股份有限公司（以下简称"独立财务顾问"） 作为本次交易的独立财务顾问，根据《上市公司重大资产重组管理办法》《公开 发行证券的公司信息披露内容与格式准则第 26 号——上市公司重大资产重组》 《深圳证券交易所上市公司自律监管指引第 8 号——重大资产重组》等文件的规 定，对上市公司本次交易相关内幕信息知情人买卖股票的情况核查如下： 一、本次交易的内幕信息知情人自查期间 本次交易的内幕信息知情人的自查期间为：上市公司本次交易股票停牌日 （2024 年 1 月 11 日）前六个月至披露重组报告书之前一日，即 202 ...

Financial Performance - Revenue for Q3 2024 was RMB 507.06 million, a decrease of 14.48% compared to the same period last year[2] - Net profit attributable to shareholders in Q3 2024 was RMB 2.30 million, a sharp decline of 98.03% year-over-year[2] - Total revenue for the first nine months of 2024 was RMB 1.48 billion, down 23.66% compared to the same period in 2023[2] - Basic earnings per share for Q3 2024 were RMB 0.0020, a decrease of 97.61% year-over-year[2] - Weighted average return on equity for Q3 2024 was 0.06%, down 2.49 percentage points compared to the same period last year[2] - Total operating income decreased to 1,478,923,011.81 yuan from 1,937,205,663.14 yuan, a decline of 23.7%[20] - Net profit attributable to parent company shareholders decreased to 139,329,413.32 yuan from 381,755,724.89 yuan, a decline of 63.5%[21] - Basic earnings per share decreased to 0.0995 yuan from 0.2738 yuan, a decline of 63.7%[21] - Total comprehensive income decreased to -46,983,781.56 yuan from 188,951,764.56 yuan, a decline of 124.9%[21] - Total operating costs decreased to 1,460,363,336.66 yuan from 1,663,779,097.25 yuan, a decline of 12.2%[20] - Income tax expense decreased to 65,606,355.63 yuan from 101,903,517.70 yuan, a decline of 35.6%[21] Cash Flow and Liquidity - Cash and cash equivalents decreased by 65.69% to RMB 1.29 billion as of September 30, 2024, due to large-term deposits, share repurchases, and R&D payments[6] - Operating cash flow for the first nine months of 2024 was negative RMB 955.58 million, a significant decline of 13,563.51% compared to the same period in 2023[2] - Operating cash flow decreased by 13,563.51% to -955.58 million yuan, primarily due to historical R&D payments by Jushi Biotech[9] - Investing cash flow decreased by 80.22% to -918.87 million yuan, mainly due to the purchase of large certificates of deposit and investment payments[9] - Financing cash flow decreased by 132.47% to -607.14 million yuan, primarily due to cash dividends and share repurchases[9] - Net increase in cash and cash equivalents decreased by 282.38% to -2,482.94 million yuan, mainly due to the purchase of large-term deposits, share repurchases, cash dividends, and R&D payments by Jushi Biotech[9] - Net cash flow from operating activities was -955,575,497.94 yuan, a significant decline from the previous period's -6,993,628.68 yuan[23] - Net cash flow from investing activities was -918,868,799.42 yuan, compared to -509,852,052.29 yuan in the previous period[23] - Net cash flow from financing activities was -607,138,248.40 yuan, a sharp contrast to the previous period's 1,869,614,031.82 yuan[24] - The net increase in cash and cash equivalents was -2,482,936,754.48 yuan, compared to 1,361,403,545.77 yuan in the previous period[24] - The ending balance of cash and cash equivalents was 1,287,253,553.48 yuan, down from 3,564,989,249.72 yuan in the previous period[24] - Cash received from tax refunds was 34,352,449.12 yuan, a decrease from 103,951,439.23 yuan in the previous period[23] - Cash paid for goods and services was 1,940,223,225.10 yuan, significantly higher than the previous period's 947,986,427.32 yuan[23] - Cash paid to employees was 196,033,464.29 yuan, a decrease from 217,185,381.31 yuan in the previous period[23] - Cash received from investments was 100,000,000.00 yuan, with no comparable figure in the previous period[23] R&D and Subsidiary Performance - R&D expenses for the subsidiary Jushi Biotech reached RMB 403.95 million in the first nine months of 2024, with a 48.40% increase in Q3 compared to Q3 2023[5] - Prepaid expenses increased by 95.83% to RMB 73.53 million, primarily due to increased R&D and engineering payments by Jushi Biotech[6] - Accounts payable decreased by 73.73% to RMB 332.17 million, mainly due to Jushi Biotech settling historical R&D payments[6] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 14,908[10] - Shijiazhuang Yiling Pharmaceutical Co., Ltd. holds 73.60% of the shares, totaling 1,033,744,394 shares[10] - Hong Kong Securities Clearing Company Limited holds 1.34% of the shares, totaling 18,862,864 shares[10] - Pan Yuhong holds 1.13% of the shares, totaling 15,900,000 shares[10] - Shijiazhuang Yiling Ou Yi Pharmaceutical Co., Ltd. holds 0.82% of the shares, totaling 11,587,212 shares[10] - The restricted shares of Shijiazhuang Yiling Pharmaceutical Co., Ltd. increased by 26,253,418 shares to a total of 157,520,510 shares, with the restriction set to be lifted on November 14, 2025[12][13] - Minority shareholders' equity increased to 934,812,050.05 yuan from 202,446,728.23 yuan, an increase of 361.6%[19] - Total equity decreased to 4,748,173,725.00 yuan from 5,483,270,450.43 yuan, a decline of 13.4%[19] Asset and Liability Changes - As of the end of Q3 2024, the company's monetary funds decreased to 1.29 billion RMB from 3.77 billion RMB at the beginning of the year[17] - Accounts receivable increased to 433.37 million RMB in Q3 2024 from 392.38 million RMB at the beginning of the year[17] - Inventory rose to 321.24 million RMB in Q3 2024 compared to 224.82 million RMB at the start of the year[17] - Fixed assets stood at 2.05 billion RMB in Q3 2024, slightly down from 2.08 billion RMB at the beginning of the year[17] - Construction in progress increased significantly to 421.60 million RMB in Q3 2024 from 228.71 million RMB at the start of the year[17] - Long-term equity investments decreased slightly to 264.22 million RMB in Q3 2024 from 267.07 million RMB at the beginning of the year[17] - Intangible assets were reported at 226.81 million RMB in Q3 2024, down from 231.59 million RMB at the start of the year[17] - Total assets decreased to 5,718,366,517.96 yuan from 7,472,208,452.03 yuan, a decline of 23.5%[18] - Total liabilities decreased to 970,192,792.96 yuan from 1,988,938,001.60 yuan, a decline of 51.2%[18] Acquisition and Fundraising Plans - The company plans to acquire 100% equity of Shiyao Baike through issuing shares and paying cash, with a transaction value of 7.6 billion RMB, where cash payment accounts for 10% and share issuance for 90%[15] - The issuance price for the acquisition is set at 20.95 RMB per share, not less than 80% of the average stock price in the 20 trading days prior to the pricing benchmark date[15] - The company intends to raise up to 1.78 billion RMB in supporting funds by issuing shares to no more than 35 qualified specific investors[15] Sales and Revenue - Sales revenue from goods and services received in cash was 1,349,883,416.06 yuan, a decrease compared to the previous period's 1,802,760,100.19 yuan[23]

石药创新制药股份有限公司 第六届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 石药创新制药股份有限公司（以下简称"公司"或"上市公司"）第六届监 事会第十五次会议（以下简称"本次会议"）于 2024 年 10 月 23 日在公司会议 室以现场方式召开，会议通知于 2024 年 10 月 14 日以专人送出、电话通知等方 式送达全体监事。 证券代码：300765 证券简称：新诺威 公告编号：2024-096 经审议，监事会认为：《2024 年第三季度报告》的内容符合法律、行政法 规、中国证券监督管理委员会和深圳证券交易所的相关规定，报告内容真实、 准确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日刊载于中国证监会指定创业板信息披露网站巨潮资 讯网（www.cninfo.com.cn）上的相关公告。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 三、备查文件 《石药创新制药股份有限公司第六届监事会第十五次会议决议》 特此公告。 会议由公司监事会主席张继勇先生主持。本次会议应出 ...

一、董事会会议召开情况 证券代码：300765 证券简称：新诺威 公告编号：2024-095 石药创新制药股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 具体内容详见公司刊载于中国证监会指定创业板信息披露网站巨潮资讯网 （www.cninfo.com.cn）上的相关公告。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 三、备查文件 《石药创新制药股份有限公司第六届董事会第二十次会议决议》 特此公告。 石药创新制药股份有限公司（以下简称"公司"或"上市公司"）第六届董 事会第二十次会议（以下简称"本次会议"）于 2024 年 10 月 23 日在公司会议室 以现场加通讯表决相结合的方式召开，会议通知于 2024 年 10 月 14 日以专人送 出、电话通知等方式送达全体董事。 会议由公司董事长姚兵先生主持，公司监事与高级管理人员列席了本次会议。 本次会议应出席董事人数 9 人，实际出席董事人数 9 人。出席董事资格、人数以 及召集、召开程序等均符合《中华人民共和国公司法》等法律法规和《石药创新 制药股份有限 ...

Group 1: Company Overview and Restructuring - The restructuring plan involves acquiring 100% equity of Shiyao Baike from three subsidiaries of Shiyao Group through a combination of cash and stock issuance, with a total transaction value of 7.6 billion CNY [3] - The cash and stock payment ratio for the acquisition is set at 10% and 90% respectively [3] - The valuation of Shiyao Baike's equity, as of June 30, 2024, is assessed at 7.622 billion CNY [3] Group 2: Product Development and Pipeline - Shiyao Baike focuses on long-acting protein drugs and has a strong R&D and commercialization capability [3] - The GLP-1 product line includes TG103 injection and Semaglutide injection, which are in Phase III clinical trials and expected to be approved starting in 2026 [3] - The company has a comprehensive layout for GLP-1 oral small molecule tablets and dual-target/triple-target products in preclinical stages [3] Group 3: Financial Performance and Commitments - The performance commitments for the acquired companies are set at a net profit of no less than 435 million CNY, 393 million CNY, and 436 million CNY for the years 2024, 2025, and 2026 respectively [4] - If the transaction is delayed beyond December 31, 2024, the profit commitments for 2025, 2026, and 2027 will be adjusted to 393 million CNY, 436 million CNY, and 502 million CNY respectively [4] Group 4: Share Buyback Progress - As of September 20, 2024, the company completed its share buyback plan with a total expenditure of approximately 321 million CNY (excluding transaction fees) [5]

证券代码： 300765 证券简称： 新诺威 石药创新制药股份有限公司投资者关系活动记录表 编号：2024-05 | --- | --- | --- | --- | |--------------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------------------| | 投 资 者 关系活 \n动类别 | □ 特定对象调研 \n□ 媒体采访 √ \n□ 新闻发布会 □ | □ 分析师会议 \n业绩说明会 \n路演活动 | | | | □ 现场参观 □ | 其他 | | | 参与单位名称 | 投资者网上提问 | | | | 时间 | 2024 年 10 月 15 | 日（周二）下午 14:00-17:00 | | | 地点 | 采用网络远程的方式参加了" 者网上集体接待日暨 | 公司通过全景网"投资者关系互动平 ...